Patents Examined by Shawquia Jackson
  • Patent number: 10894052
    Abstract: The present disclosure relates to heterocyclic compounds and methods which inhibit ATR kinase to treat or prevent cancer.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: January 19, 2021
    Assignees: Board of Regents, The University of Texas System, ChemPartner Corporation
    Inventors: Maria Emilia Di Francesco, Philip Jones, Christopher Lawrence Carroll, Suyambu Kesava Vijayan Ramaswamy, Zhijun Kang, Michael Garrett Johnson, Sarah Lively, David Lapointe
  • Patent number: 10894779
    Abstract: The present invention provides a process to enhance the productivity such as yield of radioactive fluorine labeled flutemetamol. Provided is a process for producing a radioactive fluorine labeled flutemetamol, which comprises: (a) a step of allowing a labeling precursor represented by the predetermined general formula to react with a radioactive fluoride ion in a presence of a solvent to obtain a radioactive fluorine labeled intermediate represented by the predetermined general formula, and (b) a step of removing the protecting groups from the radioactive fluorine labeled intermediate to obtain a radioactive fluorine labeled flutemetamol, in which the above step (a) is carried out at an internal temperature of reaction solution of 140° C. or higher.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: January 19, 2021
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Yuki Okumura, Gota Tonoya, Tomoyuki Matsunami, Kei Akama
  • Patent number: 10894762
    Abstract: A process for producing unsaturated nitrile, using a fluidized bed reactor and comprising a reaction step of subjecting hydrocarbon to a vapor phase catalytic ammoxidation reaction in the presence of a catalyst to produce the corresponding unsaturated nitrile, wherein when an internal space of the reactor is divided into two spaces of an upper space occupying a space from an upper end of an inlet of a cyclone to an upper end of the internal space and a lower space occupying a space below the upper end of the inlet of the cyclone and ranging to a dispersion plate, a ratio of an existing amount of the catalyst in the upper space to an existing amount of the catalyst in the lower space is 0.05 to 0.45 in the reaction step.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: January 19, 2021
    Assignee: ASAHI KASEI KABUSHIKI KAISHA
    Inventors: Sho Tamura, Dai Nagata
  • Patent number: 10895012
    Abstract: Group 4 transition metal-containing film forming compositions are disclosed comprising Group 4 transition metal precursors having the formula: wherein M is Ti, Zr, or Hf; each A is independently N, Si, B or P; each E is independently C, Si, B or P; m and n is independently 0, 1 or 2; m+n>1; each R is independently a H or a C1-C4 hydrocarbon group; each L is independently a ?1 anionic ligand selected from the group consisting of NR?2, OR?, Cp, amidinate, ?-diketonate, or keto-iminate, wherein R? is a H or a C1-C4 hydrocarbon group; and L? is NR? or O, wherein R? is a H or a C1-C4 hydrocarbon group. Also disclosed are methods of synthesizing and using the disclosed precursors to deposit Group 4 transition metal-containing films on one or more substrates via vapor deposition processes.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: January 19, 2021
    Assignee: L'Air Liquide Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude
    Inventors: Satoko Gatineau, Wontae Noh, Daehyeon Kim, Julien Gatineau, Jean-Marc Girard
  • Patent number: 10889543
    Abstract: The present invention relates to novel small molecule modulators of Nav1.6 channels of the general formulae (I), (II), (III) and (IV), and the uses thereof.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: January 12, 2021
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Fernanda Laezza, Jia Zhou, Zhiqing Liu, Syed Ali
  • Patent number: 10889589
    Abstract: Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: January 12, 2021
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Steven Wade Andrews, James F. Blake, Barbara J. Brandhuber, Julia Haas, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Allen A. Thomas, Shannon L. Winski
  • Patent number: 10889719
    Abstract: Disclosed are a fluorescent dye, a preparation method and an application thereof. The fluorescent dye has a structure of formula (I), where X and Y are independently selected from O, S, C(CH3)2 and NR6; R2 and R3 are independently hydrogen or a functional group; R1, R4, R5 and R6 are independently selected from functional groups; and Z? is a negative ion. The fluorescent dye has an ability to permeate the living cell membrane, so that it can be used in the fluorescence imaging of living cell microstructures, and can also be used in the STED super-resolution fluorescence imaging and laser scanning confocal microscopy of live cells.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: January 12, 2021
    Assignee: Shenzhen University
    Inventors: Zhigang Yang, Junle Qu
  • Patent number: 10889549
    Abstract: The invention relates to a commercially viable, cost effective and energy efficient process for the preparation of 2-(1H-Imidazol-4-yl)ethanamine or pharmaceutically acceptable salts thereof in high purity and yield via application of continuous flow technology.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: January 12, 2021
    Inventors: Sanjeev Kumar, Rajesh Kumar, Brijesh Kumar Shukla, Rajendra Singh Shekhawat, Sujay Biswas, Dharam Vir, Nirmal Kumar, Indranil Nandi
  • Patent number: 10875846
    Abstract: The present invention provides processes for the preparation of Tezacaftor, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the preparation of a compound of Formula (3), and its conversion to Tezacaftor (1).
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: December 29, 2020
    Assignee: Apotex Inc.
    Inventors: Michael R. Emmett, Prabhudas Bodhuri, Yajun Zhao, Eduardo Gustavo Cammisa, Stuart P. Green
  • Patent number: 10875850
    Abstract: Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 29, 2020
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Myriem El Qacemi, Jérôme Yves Cassayre, Thomas Pitterna, André Stoller, Peter Renold
  • Patent number: 10870616
    Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: December 22, 2020
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Thomas Scanlan, Jordan Devereaux, Andrew Placzek, Tapasree Banerji, Skylar Ferrara, James Matthew Meinig, Tania Banerji
  • Patent number: 10869860
    Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: December 22, 2020
    Assignees: VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, David Weinstein, Ekaterina Vinogradova
  • Patent number: 10870629
    Abstract: The present invention relates to an 18F-labelled compound, and a use thereof. The compound selectively binds to a prostate-specific membrane antigen (PSMA), and enables the acquisition of clear prostate cancer images in a short time when used in positron emission tomography (PET).
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: December 22, 2020
    Assignee: FUTURECHEM CO., LTD.
    Inventors: Dae Yoon Chi, Byoung Se Lee, So Young Chu, Woon Jung Jung, Hyeon Jin Jeong, Min Hwan Kim, Mi Hyun Kim, Kyo Chul Lee, Yong Jin Lee, Ji Ae Park, Ran Ji Yoo, Sang Moo Lim
  • Patent number: 10857132
    Abstract: The present invention relates to stable amorphous form of sacubitril valsartan trisodium complex and its solid dispersion compounds, processes for their preparation and pharmaceutical composition comprising the same. The present invention also relates to an improved process for the preparation of sacubitril sodium and its use in the preparation of sacubitril valsartan trisodium complex.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: December 8, 2020
    Assignee: Laurus Labs Limited
    Inventors: Ravindra Babu Bollu, Ram Thaimattam, Venkateswar Rao Challagonda, Sivarami Reddy Yasam, Pavan Kumar Seethamraju, Uma Maheswar Rao Vasireddi
  • Patent number: 10858319
    Abstract: Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X1, X2, X3, X4, and X5 may be the same or different and each is independently selected from C, N and O; each atom having a dotted line may independently have a double bond or a single bond, provided that valencies at each atom are maintained; each R1, R2, R3, R4, and R7 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X1, X2, X3, X4, and X5 are maintained; one or two R6 groups may be present and are selected from H and a substituted or unsubstituted organic group, provided that the number of R6 groups present is such that the valency of the carbon atom to which they are attached is maintained, and provided that at least one R6 is an organic group comprising an atom doub
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: December 8, 2020
    Assignee: IOMet Pharma Ltd.
    Inventors: Phillip M. Cowley, Alan Wise, Michael Kiczun, Susan Davis
  • Patent number: 10858336
    Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: December 8, 2020
    Assignee: AstaZeneca AB
    Inventors: Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Vasantha Krishna Kadambar, Chandrasekhara Reddy Chintakuntla, Andiappan Murugan, Claudio Edmundo Chuaqui
  • Patent number: 10851083
    Abstract: The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: December 1, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Frances Meredith Hocutt, Barry Eastman Leonard, Jr., Hillary M. Peltier, Victor K. Phuong, Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan, Lucy Xiumin Zhao
  • Patent number: 10844225
    Abstract: The present application relates to fluorescent dyes and their uses as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: November 24, 2020
    Assignee: Illumina Cambridge Limited
    Inventor: Nikolai Romanov
  • Patent number: 10844032
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: November 24, 2020
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Nicholas F. Pelz, Johannes Belmar, Zhiguo Bian, Edward T. Olejniczak, Stephen W. Fesik, Brian A. Chauder
  • Patent number: 10836702
    Abstract: The present technology relates to synthesis of resveratrol compositions, in particular to methods of synthesizing resveratrol salicylates such as those formed through the activation of resveratrol and salicylic acid, and cosmetic and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: November 17, 2020
    Assignee: Biocogent, LLC
    Inventors: Joseph D. Ceccoli, Michael L. Ingrassia, Christopher M. Judd, Brian R. Costello